WebMDFDA Approves Selpercatinib as First Therapy for Certain Patients With Lung, Thyroid Cancers
Based on the results of an open-label trial, selpercatinib (Retevmo) becomes the first targeted therapy to be granted accelerated approval by the FDA for use in patients with cancer who have certain tumors that have an alteration (mutation or fusion) in the RET gene.